ADIPOQ and metabolic syndrome: As a prospective study, the baseline adiponectin levels predicted de-novo MetS after a median 2.4-year follow-up (MetS vs. no MetS: females 11.0 [7.8–14.8] vs. 12.2 [9.1–15.5] μg/mL, p < 0.001; males 7.1 [4.9–9.5] vs. 8.6 [6.3–11.7] μg/mL, p < 0.001) by radioimmunoassay [17].